NEW YORK, Jan. 3, 2017 /PRNewswire/ -- The Law Offices of
Vincent Wong announce that a class
action lawsuit has been commenced in the USDC for the Northern
District of California on behalf
of investors who purchased Dynavax Technologies Corporation
(NASDAQ: DVAX) securities between March 10,
2014 and November 11,
2016.
Click here to learn about the case:
http://www.wongesq.com/pslra/dynavax-technologies-corporation. There
is no cost or obligation to you.
According to the complaint, during the Class Period Dynavax made
false and/or misleading statements and/or failed to disclose that:
(i) the phase 3 HBV-23 trial for the Company's lead vaccine product
HEPLISAV-B was not designed in accordance with the U.S. Food and
Drug Administration's concerns and issues, as pointed out in a 2013
Complete Response Letter; (ii) Dynavax failed to provide sufficient
information to the FDA in its Revised Biologics License Application
for the drug; (iii) Dynavax's resources will not be sufficient for
the Company to advance the HEPLISAV-B program on its own; and (iv)
as a result of the foregoing, the Company's financial statements,
as well as Defendants' statements about Dynavax's business,
operations, and prospects, were false and misleading and/or lacked
a reasonable basis.
If you suffered a loss in Dynavax you have until January 17, 2017 to request that the Court
appoint you as lead plaintiff. Your ability to share in any
recovery doesn't require that you serve as a lead plaintiff. To
obtain additional information, contact Vincent Wong, Esq. either via email
vw@wongesq.com, by telephone at 212.425.1140, or visit
http://www.wongesq.com/pslra/dynavax-technologies-corporation.
Vincent Wong, Esq. is an
experienced attorney that has represented investors in securities
litigations involving financial fraud and violations of shareholder
rights. Attorney advertising. Prior results do not guarantee
similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dvax-investor-alert-the-law-offices-of-vincent-wong-reminds-investors-of-a-class-action-involving-dynavax-technologies-corporation-and-a-lead-plaintiff-deadline-of-january-17-2017-300384731.html
SOURCE The Law Offices of Vincent
Wong